One of the best known communications executives in corporate America, Susman worked at Pfizer for nearly two decades after ...

Pfizer chief corporate affairs officer Sally Susman is departing the company after roughly two decades, CEO Albert Bourla ...

Pfizer (PFE) stock in focus as Sally Susman, the company's Chief Corporate Affairs Officer, plans to depart after 18 years.

According to Bloomberg, citing an email sent by Chief Executive Officer Albert Bourla on Tuesday, Susman’s responsibilities ...

They’re lending to businesses owed money that’s in effect guaranteed by the mighty US government. Pfizer’s corporate affairs chief Sally Susman is leaving after 18 years at the pharmaceutical company.

Explore daily insights on the USA TODAY crossword puzzle by Sally Hoelscher. Uncover expert takes and answers in our crossword blog.

Pfizer CEO talks Chinese due diligence, ADC synergies to justify $6B bet on 'fabulous' bispecific By Nick Paul Taylor Jun 10, 2025 9:56am Pfizer checkpoint inhibitors PD-1/L1 immuno-oncology ...

Pfizer is expected to post earnings of $0.57 per share for the current quarter, representing a year-over-year change of -5%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.7%.

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

A documentary about astronaut Sally Ride, the return of "The Gilded Age" and premiere of "We Were Liars" are some of the new television, films and music headed to a device near you this week.

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. Otsuka detailed its phase 3 data in the kidney disease immunoglobulin A nephropathy (IgAN).

Both trials were conducted by Pfizer. The Big Pharma licensed esreboxetine to Axsome for fibromyalgia in 2020 as part of a broader deal that included all the data related to depression cast-off ...